Sedec Therapeutics
Leaders in protein palmitoylation pathway science.
Leaders in protein palmitoylation pathway science.
Sedec Therapeutics is a biotechnology startup founded in 2021, headquartered in the United States, and specializing in the development of innovative therapeutics to modulate the immune cell system in autoimmune diseases and cancer immunotherapies. The company's focus on the protein palmitoylation/depalmitoylation pathway is aimed at bringing about a new generation of therapeutics for patients. Their slogan "Leaders in protein palmitoylation pathway science" underscores their commitment to pioneering advancements in this specialized area of research and development.
The company recently secured a Seed Round investment on 01 January 2023, with Plaisance Capital Management as the lead investor. This funding is a testament to the confidence investors have in Sedec Therapeutics' mission and potential to make significant strides in the biotechnology sector.
Given the increasing importance of tailored therapeutics and the potential inherent in the modulation of the immune cell system, Sedec Therapeutics is well-positioned to capitalize on emerging opportunities in autoimmune diseases and cancer immunotherapies. Their unique biological breakthrough and strategic partnerships with investors illustrate the promising trajectory of the company as it works towards addressing critical unmet medical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 | Plaisance Capital Management | 01 Jan 2023 |
No recent news or press coverage available for Sedec Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
